About one in five breast cancers express HER2 and half of these also express a steroid hormone receptor (either PR or ER), albeit less than HER2-negative, hormone-receptor-positive tumors and therefore, tend not to respond to tamoxifen treatment. Here, ERBB2 is linked to breast cancer.